SANTA BARBARA, Calif.--(BUSINESS WIRE)--May 22, 2006--Naryx Pharma, Inc. today announced the completion of a Series B2 financing in the amount of $8 million. Naryx is a biopharmaceutical company developing proprietary products for the treatment of chronic sinusitis, one of the most common chronic conditions in the U.S. today. The investor syndicate was led by Vivo Ventures with participation from Sutter Hill Ventures.
